



## HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

April 29, 2021

NEW YORK and VIENNA, Austria, April 29, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate and present at the following upcoming virtual investor conferences:

- **7th Annual Truist Securities Life Sciences Summit, May 4 – 5, 2021**  
**Fireside Chat:** May 4, 1:50pm ET
- **Bank of America 2021 Health Care Conference, May 10 – 13, 2021**  
**Presentation:** May 13, 1:15pm ET
- **Morgan Stanley Virtual Asia Healthcare Conference, May 13 - 14, 2021**
- **RBC Capital Markets Global Healthcare Conference, May 18 - 20, 2021**  
**Fireside Chat:** May 18, 9:45am ET

The live audio webcasts of the fireside chats and presentation will be available within the Investors & Media section of HOOKIPA's website at <https://ir.hookipapharma.com/events>. An archived replay will be accessible for 30 days following the event.

### About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.

HOOKIPA's proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA's viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.

HOOKIPA's non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

Find out more about HOOKIPA online at [www.hookipapharma.com](http://www.hookipapharma.com).

For further information, please contact:

#### Media

Nina Waibel  
Senior Director - Communications  
[nina.waibel@hookipapharma.com](mailto:nina.waibel@hookipapharma.com)

#### Investors

Matt Beck  
Executive Director - Investor Relations  
[matthew.beck@hookipapharma.com](mailto:matthew.beck@hookipapharma.com)